Johnson & Johnson Asr — Product liability contingency, number of claimants remained flat by 0.0% to $40.00 in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 75.0%, from $160.00 to $40.00. Over 2 years (FY 2021 to FY 2024), Asr — Product liability contingency, number of claimants shows a downward trend with a -39.2% CAGR. This is a positive signal — lower values indicate better performance for this metric.
An increase in the number of claimants suggests rising legal risk and potential future financial liabilities, while a decrease indicates that the litigation cycle is maturing or resolving.
This metric tracks the total count of individual legal claims filed against the company specifically related to the ASR...
Comparable to mass tort litigation counts or product liability claim volumes reported by other medical device or pharmaceutical companies facing class-action or multi-district litigation.
jnj_segment_asr_product_liability_contingency_number_of_claimants| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $300.00 | $300.00 | $300.00 | $250.00 | $230.00 | $190.00 | $170.00 | $160.00 | $160.00 | $160.00 | $160.00 | $160.00 | $160.00 | $60.00 | $50.00 | $40.00 | $40.00 |
| QoQ Change | — | +0.0% | +0.0% | -16.7% | -8.0% | -17.4% | -10.5% | -5.9% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | -62.5% | -16.7% | -20.0% | +0.0% |
| YoY Change | — | — | — | — | -23.3% | -36.7% | -43.3% | -30.4% | -15.8% | -5.9% | — | +0.0% | +0.0% | -62.5% | -68.8% | -75.0% | -75.0% |
We use cookies for analytics. See our Privacy and Cookie Policy.